Investigators from Illumina and Labcorp medical affairs teamed up to perform the largest real-world characterization of advanced non-small cell lung cancer using the TruSight® Oncology 500 (TSO500) assay to date. In our recently published manuscript in Frontiers, we assessed the spectrum of current FDA therapy-associated and clinical trial-associated genomic variants, along with known and novel patterns of co-mutations and co-occurrence with biomarkers predictive of immunotherapy response. We retrospectively analyzed clinical TSO 500 testing data from 7,606 NSCLC  biopsy specimens submitted for testing during standard clinical care. Our data provides further characterization of NSCLC at the genomic and immune checkpoint inhibitor response biomarker level and highlights the clinical utility of broad coverage CGP testing in detecting both known and novel facets of NSCLC to inform treatment decision-making. 

• Download

Published in: Frontiers